Skip to main content
SpringerLink
Log in

Atezolizumab bei Cisplatin-ungeeigneten Patienten mit fortgeschrittenem oder metastasiertem Urothelkarzinom

Ergebnisse der einarmigen Phase-II-Studie (IMvigor 210)

Atezolizumab for cisplatin ineligible patients with advanced and metastatic urothelial carcinoma

Results of a one-armed phase II study (IMvigor 210)

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. von der Maase H et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608

    Article  PubMed  Google Scholar 

  2. Galsky MD et al (2011) Treatment of patients with metastatic urothelial cancer ‘unfit’ for Cisplatin-based chemotherapy. J Clin Oncol 29:2432–2438

    Article  PubMed  Google Scholar 

  3. Rosenberg JE et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. De Santis M et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191–199

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinik Ulm, Prittwitzstr. 43, 89075, Ulm, Deutschland

    Felix Wezel & Christian Bolenz

Authors
  1. Felix Wezel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Bolenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix Wezel.

Ethics declarations

Interessenkonflikt

C. Bolenz erhielt Honorare für Vorträge und Beratertätigkeiten sowie Reisekostenübernahme der Firmen Janssen-Cilag, Bayer, Astellas und Roche. F. Wezel erhielt Honorare für Vorträge und Beratertätigkeiten sowie Reisekostenübernahme der Firmen Janssen-Cilag und Bayer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wezel, F., Bolenz, C. Atezolizumab bei Cisplatin-ungeeigneten Patienten mit fortgeschrittenem oder metastasiertem Urothelkarzinom. Onkologe 23, 858–860 (2017). https://doi.org/10.1007/s00761-017-0279-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-017-0279-6

Search

Navigation